Clinical Trial Update: Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating bicalutamide and raloxifene hydrochloride in prostate cancer patients undergoing surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• RALOXIFENE HYDROCHLORIDE (RALOXIFENE HYDROCHLORIDE)
• bicalutamide (bicalutamide)

Snippet

Sponsor: Mayo Clinic | Conditions: Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma | Phase 2 | Status: WITHDRAWN